Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
Tracy A. Cole, Hien Tran Zhao, Timothy J. Collier, Ivette M. Sandoval, Caryl E. Sortwell, Kathy Steece‐Collier, Brian F. Daley, Alix Booms, Jack W. Lipton, Mackenzie Welch, Melissa Berman, Luke Jandreski, Danielle L. Graham, Andreas Weihofen, Stephanie L. Celano, , Katrina L. Paumier
This paper demonstrates that antisense oligonucleotides targeting SNCA reduce alpha-synuclein production, prevent pathology, and show translational potential in non-human primates.
bioRxiv · Nov 4, 2019 · PreprintNeuroscience